Premium Nahrungsergänzungsmittel | artgerecht

Baricitinib: Uses, Dosage & Side Effects

Baricitinib is a prescription JAK inhibitor used to treat rheumatoid arthritis, atopic dermatitis, COVID-19, and alopecia areata in adults and certain pediatric patients.

Regular tips about health Regular tips about health

Things worth knowing about "Baricitinib"

Baricitinib is a prescription JAK inhibitor used to treat rheumatoid arthritis, atopic dermatitis, COVID-19, and alopecia areata in adults and certain pediatric patients.

What is Baricitinib?

Baricitinib is an orally administered medication belonging to the class of Janus kinase (JAK) inhibitors. It selectively blocks specific enzymes involved in inflammatory signaling pathways in the body. Marketed under the brand name Olumiant® by Eli Lilly and Company, it is available as film-coated tablets and is typically taken once daily.

Approved Indications

Baricitinib is approved for several immune-mediated conditions:

Rheumatoid Arthritis: Treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response to or are intolerant of one or more disease-modifying therapies.
Atopic Dermatitis (Eczema): Treatment of moderate to severe atopic dermatitis in adults and children aged 2 years and older when systemic therapy is appropriate.
COVID-19: Treatment of hospitalized adults with COVID-19 requiring supplemental oxygen or mechanical ventilation.
Alopecia Areata: Treatment of severe alopecia areata in adults.

Mechanism of Action

Baricitinib acts as a selective inhibitor of JAK1 and JAK2 enzymes. These enzymes are key components of the JAK-STAT signaling pathway, which mediates the effects of many cytokines (immune system messenger molecules). By blocking this pathway, baricitinib reduces excessive inflammatory responses without completely suppressing the immune system.

Compared to other JAK inhibitors, baricitinib demonstrates particularly high selectivity for JAK1 and JAK2, which underpins its effectiveness across the approved indications.

Dosage

The recommended dose depends on the condition being treated and individual patient factors:

Rheumatoid Arthritis: 2 mg or 4 mg once daily (based on response and tolerability)
Atopic Dermatitis (Adults): 2 mg or 4 mg once daily
Atopic Dermatitis (Children and adolescents aged 2 years and older): weight-based dosing
COVID-19: 4 mg once daily for up to 14 days or until hospital discharge
Alopecia Areata: 2 mg or 4 mg once daily

Dose adjustments may be necessary in patients with renal impairment or other comorbidities. The treating physician will determine the appropriate dose for each patient.

Side Effects

Like all medications, baricitinib can cause side effects. Common side effects include:

Increased susceptibility to infections (e.g., upper respiratory tract infections, urinary tract infections)
Elevated blood lipid levels (cholesterol, triglycerides)
Changes in blood counts (e.g., increased platelet counts)
Elevated liver enzyme levels
Nausea

Less common but serious side effects may include:

Serious infections such as herpes zoster (shingles) or opportunistic infections
Deep vein thrombosis (DVT) and pulmonary embolism
Increased cardiovascular risk
Increased risk of malignancy

Patients should undergo regular medical monitoring during treatment.

Contraindications and Precautions

Baricitinib must not be used in the following situations:

Pregnancy and breastfeeding
Active serious infections (e.g., active tuberculosis)
Severe renal impairment (GFR below 30 ml/min)
Known hypersensitivity to the active substance

Prior to initiating therapy, infectious diseases (in particular tuberculosis and hepatitis) should be excluded. Concomitant use of other immunosuppressive agents requires special caution.

Important Notes

Baricitinib is a prescription-only medication and must only be taken under medical supervision. Patients should not alter or discontinue the dose on their own. If symptoms such as fever, signs of infection, or unusual complaints arise, medical advice should be sought promptly.

References

European Medicines Agency (EMA): Summary of Product Characteristics - Olumiant® (Baricitinib), EMA/CHMP/796872/2016.
Smolen JS et al. - Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New England Journal of Medicine, 2017; 376:1321-1332.
Eli Lilly and Company: Baricitinib (Olumiant®) Product Monograph, 2023.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.